Identifying common genes and networks in multi-organ fibrosis
- PMID: 22779061
- PMCID: PMC3392050
Identifying common genes and networks in multi-organ fibrosis
Abstract
Fibroproliferative diseases of organs are poorly understood and generally lack effective anti-fibrotic treatments. Our goal was to identify the key regulatory factors in pathologic fibrosis, common between organ-based fibrotic disease. We analyzed 9 microarray datasets publicly available in the GEO datasets from lung, heart, liver and kidney fibrotic disease tissue (489 microarrays total, disease and control). We identified a set of 90 genes differentially expressed in at least five microarray datasets. We used IPA and DAVID analysis to identify gene networks and their molecular functions. A mutual information based network work activity analysis showed that a connective tissue disorders network was the most active for all types of fibrosis included in this analysis.
Conclusion: Our analysis indicates that despite different disease manifestation, organ fibrosis share a specific set of genes suggesting the potential for a common origin.
Figures



Similar articles
-
Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis.PeerJ. 2019 Mar 22;7:e6645. doi: 10.7717/peerj.6645. eCollection 2019. PeerJ. 2019. PMID: 30923657 Free PMC article.
-
A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.Genome Med. 2017 Mar 23;9(1):27. doi: 10.1186/s13073-017-0417-1. Genome Med. 2017. PMID: 28330499 Free PMC article.
-
Integrated analysis of microRNA and gene expression profiles reveals a functional regulatory module associated with liver fibrosis.Gene. 2017 Dec 15;636:87-95. doi: 10.1016/j.gene.2017.09.027. Epub 2017 Sep 14. Gene. 2017. PMID: 28919164
-
Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response.Int J Mol Sci. 2020 Nov 14;21(22):8590. doi: 10.3390/ijms21228590. Int J Mol Sci. 2020. PMID: 33202590 Free PMC article. Review.
-
Human Fibrotic Diseases: Current Challenges in Fibrosis Research.Methods Mol Biol. 2017;1627:1-23. doi: 10.1007/978-1-4939-7113-8_1. Methods Mol Biol. 2017. PMID: 28836191 Review.
Cited by
-
Drugs and Targets in Fibrosis.Front Pharmacol. 2017 Nov 23;8:855. doi: 10.3389/fphar.2017.00855. eCollection 2017. Front Pharmacol. 2017. PMID: 29218009 Free PMC article. Review.
-
Ogerin mediated inhibition of TGF-β(1) induced myofibroblast differentiation is potentiated by acidic pH.PLoS One. 2022 Jul 28;17(7):e0271608. doi: 10.1371/journal.pone.0271608. eCollection 2022. PLoS One. 2022. PMID: 35901086 Free PMC article.
-
Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women.Am J Obstet Gynecol. 2024 Sep;231(3):324.e1-324.e12. doi: 10.1016/j.ajog.2024.05.048. Epub 2024 May 31. Am J Obstet Gynecol. 2024. PMID: 38825029
-
Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF.JCI Insight. 2021 Jun 8;6(11):e141061. doi: 10.1172/jci.insight.141061. JCI Insight. 2021. PMID: 33945505 Free PMC article.
-
Dr AFC: drug repositioning through anti-fibrosis characteristic.Brief Bioinform. 2021 May 20;22(3):bbaa115. doi: 10.1093/bib/bbaa115. Brief Bioinform. 2021. PMID: 32572450 Free PMC article.
References
-
- du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 2010 Feb;9(2):129–40. - PubMed
-
- Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008 Dec 15;178(12):1257–61. - PubMed
-
- van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010 Jan;7(1):30–7. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources